Caplacizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Caplacizumab and local guidelines before prescribing.
Anti-vWF agent
Mechanism
Anti-von Willebrand factor nanobody.
Uses
Acquired thrombotic thrombocytopenic purpura.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Bleeding, epistaxis, headache.
Interactions
Anticoagulants and antiplatelets increase bleeding.
Contraindications and cautions
Active bleeding
Monitoring
Platelets, bleeding, ADAMTS13
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive; vWF concentrate
Special advice
Use with plasma exchange and immunosuppression; stop 7 days after last plasma exchange.
More from the textbook: uses, cautions and other points
- TTP - low ADAMTS13 (the enzyme that cuts von Willebrand factor) → fever, confusion or stroke, kidney injury, purpura; an emergency - urgent plasma exchange , steroids, rituximab, caplacizumab; avoid platelet transfusion (feeds clotting).
Haematology: Anatomy Physiology and Pharmacology - Immediate management: This is a haematology emergency: arrange immediate specialist discussion and urgent therapeutic plasma exchange with immunosuppression for suspected immune TTP. Caplacizumab/rituximab decisions follow the specialist protocol. Avoid routine prophylactic platelet transfusion except exceptional life-threatening …
0269-miscellaneous-conditions-a-z - TTP - plasma exchange, steroids, rituximab, caplacizumab (blocks vWF–platelet binding - bleeding risk).
Haematology: Anatomy Physiology and Pharmacology - TTP | Same-day plasma exchange; steroids; caplacizumab; no platelets unless life-threatening bleeding
Haematology: Emergencies - Caplacizumab - blocks von Willebrand factor–platelet binding (faster platelet recovery, fewer relapses; increases bleeding).
Haematology: Emergencies - Caplacizumab | Immune TTP with plasma exchange and immunosuppression; bleeding risk.
Haematology: Emergencies - Same-day plasma exchange; IV methylprednisolone; caplacizumab; rituximab.
Haematology: Emergencies - NICE TA667: Caplacizumab for acute acquired TTP
Haematology: Emergencies
Where it is discussed in the book
- Haematology: Anatomy Physiology and Pharmacology (2 mentions)
- Haematology: Emergencies (5 mentions)
- Clinical Immunology: Autoimmunity, autoantibodies and complement (1 mention)
- 0269-miscellaneous-conditions-a-z (1 mention)